Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (141-150 of 858) with videos related to

Pageof 86
Sort By:
Critical Pathways in Cardiology|March 11, 2010
Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trialsSimona Mega, Giuseppe Patti, Christopher P Cannon, et al.
European Heart Journal|October 18, 2022
Individualized therapy in statin intolerance: the key to successMaciej Banach, Christopher P Cannon, Francesco Paneni, et al.
European Heart Journal|September 7, 2006
Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trialShaheeda Ahmed, Christopher P Cannon, Sabina A Murphy, et al.
International Journal of Cardiology|April 12, 2005
Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16Olga S Gurjeva, Gene Bukhman, Sabina Murphy, et al.
Reviews in Cardiovascular Medicine|May 25, 2010
Patent foramen ovale. Incidental patent foramen ovale during cardiothoracic surgery: to repair or not to repair?Quynh A Truong, Ana C Garrido-Castro, Christopher P Cannon
American Heart Journal|November 5, 2003
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic interventionJames L Januzzi, Christopher P Cannon, Pierre Theroux, et al.
American Heart Journal|August 1, 2006
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisChristopher P Cannon, Sean P Curtis, James A Bolognese, et al.
Journal of the American College of Cardiology|July 18, 2018
The Evolving Future of PCSK9 InhibitorsRobert S Rosenson, Robert A Hegele, Sergio Fazio, et al.
JACC. Heart Failure|December 1, 2022
Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney DiseaseMario Enrico Canonico, Judith Hsia, Christopher P Cannon, et al.
Critical Pathways in Cardiology|December 20, 2007
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleedGeoffrey C Schreiner, Loren Laine, Sabina A Murphy, et al.
Pageof 86

Showing results (141-150 of 858) with videos related to

Sort By:
Pageof 86
Critical Pathways in Cardiology|March 11, 2010
Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trialsSimona Mega, Giuseppe Patti, Christopher P Cannon, et al.
European Heart Journal|October 18, 2022
Individualized therapy in statin intolerance: the key to successMaciej Banach, Christopher P Cannon, Francesco Paneni, et al.
European Heart Journal|September 7, 2006
Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trialShaheeda Ahmed, Christopher P Cannon, Sabina A Murphy, et al.
International Journal of Cardiology|April 12, 2005
Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16Olga S Gurjeva, Gene Bukhman, Sabina Murphy, et al.
Reviews in Cardiovascular Medicine|May 25, 2010
Patent foramen ovale. Incidental patent foramen ovale during cardiothoracic surgery: to repair or not to repair?Quynh A Truong, Ana C Garrido-Castro, Christopher P Cannon
American Heart Journal|November 5, 2003
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic interventionJames L Januzzi, Christopher P Cannon, Pierre Theroux, et al.
American Heart Journal|August 1, 2006
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisChristopher P Cannon, Sean P Curtis, James A Bolognese, et al.
Journal of the American College of Cardiology|July 18, 2018
The Evolving Future of PCSK9 InhibitorsRobert S Rosenson, Robert A Hegele, Sergio Fazio, et al.
JACC. Heart Failure|December 1, 2022
Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney DiseaseMario Enrico Canonico, Judith Hsia, Christopher P Cannon, et al.
Critical Pathways in Cardiology|December 20, 2007
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleedGeoffrey C Schreiner, Loren Laine, Sabina A Murphy, et al.
Pageof 86